Answers are grounded in this paper and cite their sources.
Hemophilia A is an X-linked congenital bleeding disorder caused by a deficiency or absence of coagulation factor VIII. In children who are in the first year of life, bleeding into the head accounts for 12.8–17.7 % of cases, and up to 45.5 % of them are intracranial bleeding in contrast to adult patients, in whom joints are the most frequent localization of bleeding. The first 2 years of life are the most dangerous in relation to intracranial bleeding for a child with hemophilia and the provision of full preventive treatment is extremely important for this time. Aim of the study – present the first experience of using emicizumab as primary prophylaxis in a child of the first year of life with hemophilia A. A patient born in 2020 with a severe hemophilia A had two post-traumatic bleeding that required hospitalization and replacement therapy. We decided to start primary prophylaxis with emicizumab at the age of 10 months. There were not spontaneous bleedings during 8 months of emicizumab usage. Post-traumatic bleeding did not require hospitalization and additional therapy. The clinical case demonstrates that emicizumab is effective and safe in infant who have not previously received prophylactic treatment.
No takes yet. Share an insight, caveat, or question.
Andreeva et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: